|
 |
 |
 |
 |
|
 |
|
|
|
|
For more than 100 years, Roche has developed products that have been milestones
in drug
therapy. Our focus on innovation is still evident in our products and services today – we are global
market leader in a number of major therapeutic areas. Eight of our ten best-selling drugs were the first
marketed products of their kind, and some are still unique.
Our products
and services
can help to prevent and cure diseases, hasten recovery or alleviate symptoms – helping to improve quality
of life and even save lives. They can also provide economic benefits by reducing treatment times, minimising
hospital stays and helping people return to work faster.
Our Pharmaceuticals
Division
discovers, develops, manufactures and markets our innovative medicines. We are particularly focused
on molecular medicine, which helps provide more targeted therapies and personalised healthcare. Find
out more about specific disease areas and selected Roche prescription
drugs.
Roche
Diagnostics
supplies products and services for scientific research, clinical laboratories and patient self-monitoring.
Diagnostics – especially modern genetic tests – play an increasingly important role in healthcare. They
enable doctors to detect early on whether patients are predisposed to disease, to establish whether
patients will respond to a particular medicine and to monitor how they respond to treatment.
The
more we know about the causes of disease, the more accurately we can diagnose them. As the world’s leading
supplier of such tests, Roche Diagnostics aims to give doctors, patients and healthcare payers the best
possible access to reliable information so they can make rapid and appropriate clinical decisions.
Supporting
innovation
Innovation is the core of our business strategy and the secret of our
success.
Patients’ health is our top priority – driving our efforts to create innovative solutions to address
unmet medical needs and thus add real value back to society.
We also
have a network of
external innovation partners. We invest in emerging technologies that we identify as critical to our
R&D pipeline, and work with commercial and academic partners that complement our areas of focus
in research.
|
|
|
|
|
|
|
|
print this page